The Modified Telephone-Administered Minnesota Cognitive Acuity Screen for Mild Cognitive Impairment

Journal of Geriatric Psychiatry and Neurology
Sarah PillemerGeoffrey Tremont

Abstract

This study aimed to compare the sensitivity and specificity of a modified version of the Minnesota Cognitive Acuity Screen (MCAS-m), by adding learning and recognition memory components, to the original version MCAS to distinguish amnestic mild cognitive impairment (aMCI) from healthy controls (HCs). A total of 30 individuals with aMCI and 30 HCs underwent neuropsychological testing, neurologic examination, laboratory, and brain imaging tests. Once diagnosis was confirmed, participants completed the MCAS and MCAS-m in counterbalanced order. The average administration time was 12.6 minutes for the MCAS and 13.5 minutes for the MCAS-m. Receiver operating characteristic curve analyses showed that the MCAS-m demonstrated 97% sensitivity and 97% specificity for distinguishing between aMCI and HC versus 97% and 87%, respectively, for the original MCAS in this sample. Both the MCAS and the MCAS-m were highly sensitive when distinguishing between normal cognition and aMCI; however, the MCAS-m demonstrated a 10% increase in specificity compared to the original version. Improved specificity is particularly relevant to screening in larger community samples with lower base rates of MCI than clinic populations. This modified screening measu...Continue Reading

References

Dec 26, 2001·Archives of Neurology·R C PetersenB Winblad
Oct 24, 2002·Acta Psychiatrica Scandinavica·J BischkopfM C Angermeyer
Jan 21, 2004·Archives of Neurology·Michael GrundmanUNKNOWN Alzheimer's Disease Cooperative Study
Aug 19, 2004·Dementia and Geriatric Cognitive Disorders·P MaruffJon Currie
Jan 1, 1950·Cancer·W J YOUDEN
Aug 13, 2008·Alzheimer Disease and Associated Disorders·Kevin DuffWilliam H Adams
Apr 9, 2009·Neuropsychology, Development, and Cognition. Section B, Aging, Neuropsychology and Cognition·Laura A RabinRobert B Santulli
May 7, 2009·Journal of Geriatric Psychiatry and Neurology·Sarah E CookKarin J M McCoy
Jul 7, 2010·Journal of Clinical and Experimental Neuropsychology·Geoffrey TremontHolly James Westervelt
May 11, 2011·Archives of Neurology·Jennifer J ManlyRichard Mayeux
Dec 1, 2011·American Journal of Alzheimer's Disease and Other Dementias·Geoffrey TremontBrian R Ott
Jul 10, 2012·Current Psychiatry Reports·Yonas E Geda

❮ Previous
Next ❯

Citations

Oct 28, 2020·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Anne R CarlewColin Munro Cullum
Mar 3, 2020·Journal of Geriatric Oncology·Priscille Le BonBérengère Beauplet

❮ Previous
Next ❯

Software Mentioned

R
MCAS

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Related Papers

American Journal of Alzheimer's Disease and Other Dementias
Geoffrey TremontBrian R Ott
American Journal of Alzheimer's Disease and Other Dementias
Michael S RafiiDouglas Galasko
Journal of Geriatric Psychiatry and Neurology
Beth A SpringateBrian R Ott
© 2022 Meta ULC. All rights reserved